NCT00422799View on ClinicalTrials.gov

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 30, 2006

Primary Completion Date

October 9, 2015

Study Completion Date

October 9, 2015

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Bortezomib

Once weekly for 3 weeks

DRUG

Rituximab

Intravenously once a week for the first and fourth weeks of a cycle

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER